3-Year Manhunt Ends as Key Figure in ₹25 Crore Fake Cancer Drug Syndicate Captured
In a significant breakthrough, Delhi Police have apprehended Sabir Alam, a central figure in a ₹25 crore counterfeit cancer drug operation, after a relentless three-year pursuit. Alam was arrested on May 20 in Bardhaman, West Bengal, while on his honeymoon, following a critical tip-off and extensive surveillance.
The investigation into this illicit network began in November 2022, leading to the arrest of 14 individuals, including two doctors. Authorities uncovered a clandestine manufacturing unit in Sonipat, Haryana, and a warehouse in Tronica City, Uttar Pradesh, where counterfeit medications were produced and stored. The syndicate’s modus operandi involved refilling empty vials of expensive cancer drugs with inexpensive substances like antifungal agents and selling them at exorbitant prices ranging from ₹1 lakh to ₹3 lakh per vial.
Alam played a pivotal role in distributing these fake medications in Kolkata and coordinating shipments to Bangladesh, where they were supplied to an associate identified as Dr. Rasel. He also managed financial transactions, collecting payments from unsuspecting patients and transferring proceeds to co-conspirators after retaining his share.
Following the arrest of his associates, Alam went into hiding, maintaining a low profile. His capture marks a significant milestone in dismantling the counterfeit drug network that jeopardized the lives of countless cancer patients.
Looking for chemical products? Let suppliers reach out to you!
2026-07-10
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Alipay, Baidu, and iFlytek Win Big—As the Government Spends $1.1 Billion on AI Healthcare, Is This a Lifeline or a Feeding Frenzy for Tech Giants?
-
Sun Pharma’s Secret Sauce: Solve the Specific, Win the Market
-
The Oral GLP-1 Cage Match: Orforglipron vs Rybelsus
-
Sun Pharma’s Winning Formula: Precision Over Expansion
-
Merck to Lay Off 150 Workers at US Gardasil Plant Amid Sales Weakness
-
The Pill That Could Swallow the Needle: Novo Nordisk Launches Oral Wegovy in U.S. Weight-Loss Revolution
-
The $6 Billion Gold Rush: Generic Semaglutide Set to Reshape Global Pharma After Patent Cliff
-
AstraZeneca India Eyes ₹3,400 Crore Bengaluru Sale
-
Iran Conflict Leaves a Long Shadow on Drug Supply
-
Sun Pharma’s Organon Bid Would Redraw Indian Pharma M&A
Recommend Reading
-
4 Pharma Firms Lose Licenses in Jammu and Kashmir Amid Illegal Drug Sales Crackdown
-
A Faster Route to Diabetes Drug Chemistry
-
Vertex Buys Crinetics for $10 Billion: Rare Disease M&A Is Back
-
China’s Hybio Takes Generic Tirzepatide to FDA: Lilly’s GLP-1 Fortress Gets a Warning Shot
-
Medicare’s $50 GLP-1 Door Opens: Weight-Loss Drug Demand Just Got Bigger
-
Premium Global Chemical Sourcing Requests (07-10May, 2026)
-
This Week's Caustic Soda Prices Consolidate (5.18-5.22)
-
Supply-Demand Dynamics Drive Slight Rise in Toluene Market
-
Since May, the natural rubber market has shown a pattern of initial strength followed by weakness, with prices fluctuating at high levels.
-
Polyester Bottle Flakes Hit a Weekly High Midweek Before Falling Back